Opicapone

New patent, Opicapone, WO 2019123066, Unichem

It’s only fair to share… New patent, Opicapone, WO 2019123066, Unichem WO-2019123066 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION Process for the preparation of opicapone and its intermediates, useful for treating parkinson’s disease. Bial-Portela has developed and launched opicapone, for treating Parkinson’s disease. Opicapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, use as adjunctive therapy for parkinson’s disease. Opicapone was …

It’s only fair to share… Opicapone 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide BIA-9-1067; ONO-2370; BIA-91067 CAS No.923287-50-7 MF C15H10Cl2N4O6 MW: 411.9977 TRADE NAME (Ongentys®) Approved EU 2016-06-24 BIAL PORTELA PORTELA & CA. S.A. [PT/PT]; Av. Da Siderurgia Nacional, P-4745-457 S. Mamede do Coronado (PT) LEARMONTH, David Alexander; (PT). KISS, Laszlo Erno; (PT). LEAL PALMA, Pedro Nuno; (PT). DOS SANTOS FERREIRA, Humberto; (PT). …